Allogene Therapeutics, Inc.
NASDAQ:ALLO
2.91 (USD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | 2019 Q2 | 2019 Q1 | 2018 Q4 | 2018 Q3 | 2018 Q2 | 2018 Q1 | 2017 Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0.022 | 0.021 | 0.043 | 0.044 | 0.052 | 0.047 | 0.049 | 0.086 | 0.061 | 0.051 | 0.049 | 0.044 | 38.345 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 3.644 | 3.555 | 54.661 | 3.572 | 3.793 | 3.714 | 3.308 | 4.413 | 4.849 | 60.156 | 4.242 | 58.72 | 2.351 | 3.925 | 52.228 | 51.421 | 47.296 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| -3.644 | -3.533 | -54.64 | -3.529 | -3.749 | -3.662 | -3.261 | -4.364 | -4.763 | -60.095 | -4.191 | -58.671 | -2.307 | 34.42 | -52.228 | -51.421 | -47.296 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | -160.591 | -2,601.905 | -82.07 | -85.205 | -70.423 | -69.383 | -89.061 | -55.384 | -985.164 | -82.176 | -1,197.367 | -52.432 | 0.898 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 46.711 | 48.704 | 54.661 | 45.977 | 62.038 | 80.238 | 75.419 | 63.641 | 57.171 | 60.156 | 53.983 | 58.72 | 52.29 | 55.183 | 52.228 | 51.421 | 47.296 | 42.042 | 49.363 | 39.995 | 31.774 | 23.403 | 18.503 | 10.87 | 122.486 | 0 | 0 |
| General & Administrative Expenses
| 16.087 | 17.267 | 17.224 | 17.041 | 18.524 | 18.884 | 21.002 | 18.897 | 19.509 | 19.897 | 19.961 | 18.999 | 18.783 | 16.363 | 17.134 | 16.619 | 15.862 | 15.641 | 15.212 | 15.016 | 14.187 | 13.058 | 14.543 | 11.317 | 12.526 | 2.597 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 16.087 | 17.267 | 17.224 | 17.041 | 18.524 | 18.884 | 21.002 | 18.897 | 19.509 | 19.897 | 19.961 | 18.999 | 18.783 | 16.363 | 17.134 | 16.619 | 15.862 | 15.641 | 15.212 | 15.016 | 14.187 | 13.058 | 14.543 | 11.317 | 12.526 | 2.597 | 0.002 |
| Other Expenses
| 0.085 | -0.929 | -10.348 | -4.545 | -1.249 | -1.693 | -1.23 | -1.661 | 1.492 | -0.35 | -1.161 | -0.909 | -0.531 | -0.325 | -0.766 | -0.162 | -0.156 | -0.058 | -0.268 | 0 | 0 | 0 | -1.796 | -19.415 | 0 | 0 | 0 |
| Operating Expenses
| 62.798 | 65.971 | 71.885 | 63.018 | 80.562 | 99.122 | 96.421 | 82.538 | 76.68 | 80.053 | 73.944 | 77.719 | 71.073 | 71.546 | 69.362 | 68.04 | 63.158 | 57.683 | 64.575 | 55.011 | 45.961 | 36.461 | 33.046 | 22.187 | 135.012 | 2.597 | 0.002 |
| Operating Income
| -66.442 | -69.504 | -71.864 | -62.975 | -80.518 | -99.07 | -96.374 | -82.489 | -76.594 | -79.992 | -73.893 | -77.67 | -71.029 | -33.201 | -69.362 | -68.04 | -63.158 | -57.683 | -64.575 | -55.011 | -45.961 | -36.461 | -33.046 | -22.187 | -135.012 | -2.597 | -0.002 |
| Operating Income Ratio
| 0 | -3,159.273 | -3,422.095 | -1,464.535 | -1,829.955 | -1,905.192 | -2,050.511 | -1,683.449 | -890.628 | -1,311.344 | -1,448.882 | -1,585.102 | -1,614.295 | -0.866 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.084 | 4.504 | -13.914 | -4.545 | -1.249 | 0.366 | 1.527 | -0.659 | 1.807 | 0.142 | -1.161 | -0.909 | -0.531 | -0.325 | -0.766 | -0.162 | -0.156 | -0.058 | -0.268 | 4.309 | 4.559 | 4.825 | -1.796 | -19.415 | 0.11 | 0 | 0 |
| Income Before Tax
| -66.358 | -65 | -85.778 | -61.315 | -77.989 | -98.704 | -94.847 | -83.148 | -74.787 | -79.85 | -74.868 | -78.186 | -70.936 | -33.015 | -68.57 | -66.197 | -60.974 | -54.48 | -61.185 | -50.702 | -41.402 | -31.636 | -30.626 | -43.497 | -134.902 | -2.597 | -0.002 |
| Income Before Tax Ratio
| 0 | -2,954.545 | -4,084.667 | -1,425.93 | -1,772.477 | -1,898.154 | -2,018.021 | -1,696.898 | -869.616 | -1,309.016 | -1,468 | -1,595.633 | -1,612.182 | -0.861 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -0 | 3.512 | -0.065 | -6.205 | -3.778 | -0.366 | -1.527 | -1.002 | -0.315 | -0.142 | -4.428 | -0.393 | -0.624 | -0.511 | -3.402 | -3.815 | -2.34 | -3.261 | -0.155 | 0.033 | -0.159 | -0.05 | -0.117 | -16.057 | 0 | -2.597 | 0 |
| Net Income
| -66.358 | -65 | -85.778 | -61.315 | -77.989 | -98.338 | -93.32 | -82.146 | -74.472 | -79.708 | -74.868 | -78.186 | -70.936 | -33.015 | -68.57 | -66.197 | -60.974 | -54.48 | -61.03 | -50.735 | -41.243 | -31.586 | -30.509 | -43.497 | -134.902 | -2.597 | -0.002 |
| Net Income Ratio
| 0 | -2,954.545 | -4,084.667 | -1,425.93 | -1,772.477 | -1,891.115 | -1,985.532 | -1,676.449 | -865.953 | -1,306.689 | -1,468 | -1,595.633 | -1,612.182 | -0.861 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.35 | -0.38 | -0.51 | -0.37 | -0.53 | -0.68 | -0.65 | -0.57 | -0.52 | -0.56 | -0.54 | -0.57 | -0.53 | -0.25 | -0.53 | -0.52 | -0.53 | -0.5 | -0.58 | -0.5 | -0.41 | -0.32 | -0.37 | -0.38 | -1.19 | -0.059 | 0 |
| EPS Diluted
| -0.35 | -0.38 | -0.51 | -0.37 | -0.53 | -0.68 | -0.65 | -0.57 | -0.52 | -0.56 | -0.54 | -0.57 | -0.53 | -0.25 | -0.53 | -0.52 | -0.53 | -0.5 | -0.58 | -0.5 | -0.41 | -0.32 | -0.37 | -0.38 | -1.19 | -0.059 | 0 |
| EBITDA
| -62.798 | -65.949 | -68.452 | -59.403 | -76.875 | -99.07 | -96.374 | -78.629 | -72.919 | -76.3 | -73.893 | -75.34 | -69.065 | -31.283 | -69.362 | -68.04 | -61.27 | -55.639 | -61.185 | -49.374 | -45.961 | -35.766 | -30.626 | -39.636 | -134.562 | -2.597 | -0.002 |
| EBITDA Ratio
| 0 | -2,997.682 | -3,259.619 | -1,381.465 | -1,747.159 | -1,905.192 | -2,050.511 | -1,604.673 | -847.895 | -1,250.82 | -1,448.882 | -1,537.551 | -1,569.659 | -0.816 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |